JP2025502614A - 縮合ピロリジンサイコプラストゲンとその使用 - Google Patents

縮合ピロリジンサイコプラストゲンとその使用 Download PDF

Info

Publication number
JP2025502614A
JP2025502614A JP2024533214A JP2024533214A JP2025502614A JP 2025502614 A JP2025502614 A JP 2025502614A JP 2024533214 A JP2024533214 A JP 2024533214A JP 2024533214 A JP2024533214 A JP 2024533214A JP 2025502614 A JP2025502614 A JP 2025502614A
Authority
JP
Japan
Prior art keywords
compound
pharma
solvate
acceptable salt
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502614A5 (https=
Inventor
アーロン パウエル,ノエル
ヒチル,ミラン
Original Assignee
デリックス セラピューティクス,インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デリックス セラピューティクス,インク. filed Critical デリックス セラピューティクス,インク.
Publication of JP2025502614A publication Critical patent/JP2025502614A/ja
Publication of JP2025502614A5 publication Critical patent/JP2025502614A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • C07D491/147Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024533214A 2021-12-15 2022-12-14 縮合ピロリジンサイコプラストゲンとその使用 Pending JP2025502614A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163290037P 2021-12-15 2021-12-15
US63/290,037 2021-12-15
US202263387225P 2022-12-13 2022-12-13
US63/387,225 2022-12-13
PCT/US2022/052879 WO2023114320A1 (en) 2021-12-15 2022-12-14 Fused pyrrolidine psychoplastogens and uses thereof

Publications (2)

Publication Number Publication Date
JP2025502614A true JP2025502614A (ja) 2025-01-28
JP2025502614A5 JP2025502614A5 (https=) 2025-12-22

Family

ID=86773439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533214A Pending JP2025502614A (ja) 2021-12-15 2022-12-14 縮合ピロリジンサイコプラストゲンとその使用

Country Status (9)

Country Link
EP (1) EP4448532A4 (https=)
JP (1) JP2025502614A (https=)
KR (1) KR20240150418A (https=)
AU (1) AU2022415426A1 (https=)
CA (1) CA3239571A1 (https=)
IL (1) IL313457A (https=)
MX (1) MX2024007220A (https=)
TW (1) TW202333736A (https=)
WO (1) WO2023114320A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023014630A (es) 2021-06-08 2024-01-30 Atai Therapeutics Inc Activadores de dimetoxifenilalquilamina de receptores de serotonina.
IL313455A (en) 2021-12-15 2024-08-01 Delix Therapeutics Inc Phenoxy and benzyloxy modified psychroplastogens and their uses
EP4457203A4 (en) 2021-12-27 2025-12-17 Atai Therapeutics Inc AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
US12343319B2 (en) 2023-05-01 2025-07-01 Atai Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0808312T3 (da) * 1995-02-02 2001-02-12 Smithkline Beecham Plc Indolderivater som 5-HT-receptorantagonist
AR023574A1 (es) * 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
WO2002024700A2 (en) * 2000-09-20 2002-03-28 Pharmacia & Upjohn Company SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES
EP1632491A1 (en) * 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
WO2021076572A1 (en) * 2019-10-14 2021-04-22 The Regents Of The University Of California Ergoline-like compounds for promoting neural plasticity

Also Published As

Publication number Publication date
TW202333736A (zh) 2023-09-01
CA3239571A1 (en) 2023-06-22
WO2023114320A1 (en) 2023-06-22
EP4448532A1 (en) 2024-10-23
KR20240150418A (ko) 2024-10-15
EP4448532A4 (en) 2025-12-24
AU2022415426A1 (en) 2024-07-25
MX2024007220A (es) 2024-08-27
IL313457A (en) 2024-08-01

Similar Documents

Publication Publication Date Title
JP2025502614A (ja) 縮合ピロリジンサイコプラストゲンとその使用
WO2021076572A1 (en) Ergoline-like compounds for promoting neural plasticity
WO2021252692A1 (en) Isotryptamine psychoplastogens and uses thereof
KR20230066311A (ko) 삼환형 사이코플라스토겐 및 이의 용도
JP2024515614A (ja) 脳障害を治療するための四環式化合物
US12295959B2 (en) Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
US20250051276A1 (en) Aryloxy psychoplastogens and uses thereof
WO2023114858A1 (en) Benzofuran and benzothiophene psychoplastogens and uses thereof
WO2023114844A1 (en) Imidazopyridine psychoplastogens and uses thereof
CN118696047A (zh) 稠合吡咯烷精神重塑剂及其用途
WO2023114325A1 (en) Constrained amine psychoplastogens and uses thereof
WO2024258995A2 (en) Fused tetrahydroazepine psychoplastogens and uses thereof
CN118742551A (zh) 苯氧基和苄氧基取代的精神重塑剂及其用途
WO2024258988A2 (en) Serotonin releasing compounds and uses thereof
WO2026072584A1 (en) Methods of using phenoxy and benzyloxy substituted neuroplastogens
CN116507625A (zh) 异色胺神经可塑剂及其用途
WO2025137596A1 (en) Mixed serotonin receptor binders for treatment of psychotic disorders
WO2025137639A1 (en) Mixed serotonin receptor binders for treatment of psychotic disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251212